Clinical Study

K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy

Volume 13, Issue 13   November 2012
Pages 1235 - 1243
http://dx.doi.org/10.4161/cbt.21813
Keywords: B-Raf mutation, K-Ras mutation, RAS/RAF/mitogen-activated protein kinase, anti-EGFR therapy, colorectal cancer, irinotecan, oxaliplatin
Authors: Rafał Stec, Lubomir Bodnar, Radosław Charkiewicz, Jan Korniluk, Marta Rokita, Marta Smoter, Marzena Ciechowicz, Lech Chyczewski, Jacek Nikliński, Wojciech Kozłowski and Cezary Szczylik

View affiliations

Abstract:
Background: CRC caused more than 600,000 estimated deaths in 2008. Dysregulated signaling through the RAS/RAF/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway due to mutations in K-Ras and B-Raf are common events in CRC. Methods: Incidence of mutations in codons 12 and 13 of K-Ras and exons 11 and 15 of B-Raf were analyzed in amplified PCR products from primary tumors of 273 patients with CRC, and their prognostic and predictive significance was assessed. The prognostic role of clinical and pathological factors was also examined. Results: K-Ras mutations were present in 89 patients (32.6%), of whom 76 (85.4%) had mutations in codon 12 and 10 (11.2%) had mutations in codon 13. B-Raf gene mutations were present in 17 patients (6.9%), of whom 6 (35.3%) had mutations in exon 15. Multivariate analysis revealed a predictive significance for K-Ras mutations with respect to time to progression in patients treated with irinotecan and oxaliplatin as first-line chemotherapy. There was no predictive significance for B-Raf gene mutation status in these patients. The following risk factors were found to affect overall survival (OS) rates: primary tumor location, lymph node involvement grade, carcinoembryonic antigen (CEA) level before treatment, and performance status according to WHO criteria. Conclusions: Based on the results of this study, K-Ras mutation status may be a suitable indicator of patient eligibility and a prognostic indicator for responsiveness to anti-EGFR therapy alone, or in combination with chemotherapy. Also, K-Ras mutation status may predict time to progression in patients treated with irinotecan and oxaliplatin.

Received: May 15, 2012; Accepted: August 10, 2012; Published Online: August 22, 2012

Preview:



Comments

Please Log In to comment on this article.
If you do not have an account Create One Here.
blog comments powered by Disqus
Advertisements